Skip to main content

Viatris Inc Creon ® revenue

  • VTRS · Nasdaq
  • Pharmaceuticals
  • S&P 500
$20.82+0.73%Close 13 Nov 2026

Creon ® revenue at Viatris Inc came to $98.1M for the quarter to 30 Sep 2026, up 5.4% from a year earlier.

As Viatris Inc reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 5 Nov 2026.

By quarter

$80.6MDec 2023$75.0MMar 2024$78.2MJun 2024$84.6MSep 2024$90.4MDec 2024$82.4MMar 2025$91.4MJun 2025$93.1MSep 2025$98.9MDec 2025$97.4MMar 2026$97.4MJun 2026$98.1MSep 2026
Viatris Inc Creon ® revenue, every reported period
Period endingCreon ® revenueChange on a yearFiled
30 Sep 2026$98.1Mup 5.4%5 Nov 2026
30 Jun 2026$97.4Mup 6.6%6 Aug 2026
31 Mar 2026$97.4Mup 18.2%7 May 2026
31 Dec 2025$98.9Mup 9.4%26 Feb 2026
30 Sep 2025$93.1Mup 10.0%6 Nov 2025
30 Jun 2025$91.4Mup 16.9%7 Aug 2025
31 Mar 2025$82.4Mup 9.9%8 May 2025
31 Dec 2024$90.4Mup 12.2%27 Feb 2025
30 Sep 2024$84.6Mup 9.2%7 Nov 2024
30 Jun 2024$78.2Mup 5.5%8 Aug 2024
31 Mar 2024$75.0Mup 3.2%9 May 2024
31 Dec 2023$80.6Mup 4.0%28 Feb 2024
30 Sep 2023$77.5Mup 1.4%8 Nov 2023
30 Jun 2023$74.1Mdown 1.7%7 Aug 2023
31 Mar 2023$72.7Mdown 2.7%8 May 2023
31 Dec 2022$77.5Mdown 8.9%27 Feb 2023
30 Sep 2022$76.4Mdown 5.8%7 Nov 2022
30 Jun 2022$75.4Mdown 6.6%8 Aug 2022
31 Mar 2022$74.7Mup 6.9%9 May 2022
31 Dec 2021$85.1M—28 Feb 2022
30 Sep 2021$81.1M—8 Nov 2021
30 Jun 2021$80.7M—9 Aug 2021
31 Mar 2021$69.9M—10 May 2021

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Viatris Inc: Brands revenue · Generics revenue · Lipitor revenue · Norvasc revenue · EpiPen® Auto-Injectors revenue · Lyrica ® revenue · Viagra ® revenue · Influvac ® revenue · Zoloft ® revenue · Yupelri ® revenue · Celebrex ® revenue · Effexor ® revenue · Xalabrands revenue · Xanax ® revenue · Amitiza ® revenue · Dymista ® revenue · Developed Markets Segment revenue · Greater China revenue · Emerging Markets Segment revenue · Japan, Australia and New Zealand Segment revenue · financial statements

Every KPI and segment of VTRS, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.